RetaMaps

Carolina Physicians Weight Loss

Carolina Physicians Weight Loss — Greenville · 103 S Venture Drive · Greenville, SC 29615

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Carolina Physicians Weight Loss in Greenville, SC (103 S Venture Drive) is a physician-assisted, cash-pay medical weight-loss program built around FDA-approved semaglutide (a once-weekly injection) used with diet and exercise. Official pages name semaglutide only—not tirzepatide—and describe the program for adults with overweight or obesity. No clinician names are published on the homepage; this is an in-person clinic listing, not a telehealth brand.

Services & access

Advertises semaglutide todayYes
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay acceptedYes
Accepts insurance — per practice websiteNot listed
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Nearby providers in Greenville

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs